Jeff Yass’s Aldeyra Therapeutics ALDX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $141K | Sell |
66,100
-167,900
| -72% | -$289K | ﹤0.01% | 12255 |
|
|
2026
Q1 | $395K | Buy |
234,000
+191,900
| +456% | +$841K | ﹤0.01% | 10249 |
|
|
2025
Q4 | $218K | Buy |
+42,100
| New | +$216K | ﹤0.01% | 10694 |
|
|
2025
Q3 | – | Sell |
-16,600
| Closed | -$63.6K | – | 12272 |
|
|
2025
Q2 | $63.6K | Sell |
16,600
-21,400
| -56% | -$55.3K | ﹤0.01% | 12035 |
|
|
2025
Q1 | $219K | Sell |
38,000
-1,700
| -4% | -$10K | ﹤0.01% | 10764 |
|
|
2024
Q4 | $198K | Buy |
39,700
+1,800
| +5% | +$9.24K | ﹤0.01% | 10736 |
|
|
2024
Q3 | $204K | Buy |
37,900
+21,500
| +131% | +$102K | ﹤0.01% | 10432 |
|
|
2024
Q2 | $54.3K | Buy |
16,400
+3,100
| +23% | +$12.1K | ﹤0.01% | 11375 |
|
|
2024
Q1 | $43.5K | Sell |
13,300
-29,100
| -69% | -$95.7K | ﹤0.01% | 11608 |
|
|
2023
Q4 | $149K | Sell |
42,400
-54,800
| -56% | -$169K | ﹤0.01% | 10985 |
|
|
2023
Q3 | $649K | Sell |
97,200
-54,200
| -36% | -$402K | ﹤0.01% | 7617 |
|
|
2023
Q2 | $1.27M | Buy |
151,400
+91,700
| +154% | +$903K | ﹤0.01% | 6140 |
|
|
2023
Q1 | $593K | Buy |
59,700
+8,700
| +17% | +$61.5K | ﹤0.01% | 8155 |
|
|
2022
Q4 | $355K | Sell |
51,000
-40,800
| -44% | -$233K | ﹤0.01% | 8690 |
|
|
2022
Q3 | $490K | Buy |
91,800
+45,700
| +99% | +$274K | ﹤0.01% | 8544 |
|
|
2022
Q2 | $184K | Sell |
46,100
-183,200
| -80% | -$630K | ﹤0.01% | 10754 |
|
|
2022
Q1 | $1.02M | Buy |
229,300
+113,700
| +98% | +$453K | ﹤0.01% | 7063 |
|
|
2021
Q4 | $462K | Buy |
115,600
+69,600
| +151% | +$531K | ﹤0.01% | 9414 |
|
|
2021
Q3 | $404K | Sell |
46,000
-95,100
| -67% | -$873K | ﹤0.01% | 9915 |
|
|
2021
Q2 | $1.6M | Sell |
141,100
-77,700
| -36% | -$934K | ﹤0.01% | 6470 |
|
|
2021
Q1 | $2.6M | Buy |
218,800
+127,300
| +139% | +$1.47M | ﹤0.01% | 5294 |
|
|
2020
Q4 | $628K | Buy |
91,500
+56,200
| +159% | +$395K | ﹤0.01% | 7783 |
|
|
2020
Q3 | $262K | Buy |
35,300
+22,200
| +169% | +$143K | ﹤0.01% | 8972 |
|
|
2020
Q2 | $55K | Buy |
13,100
+1,500
| +13% | +$5.48K | ﹤0.01% | 9722 |
|
|
2020
Q1 | $29K | Sell |
11,600
-48,700
| -81% | -$219K | ﹤0.01% | 9831 |
|
|
2019
Q4 | $350K | Buy |
60,300
+40,200
| +200% | +$232K | ﹤0.01% | 7704 |
|
|
2019
Q3 | $106K | Sell |
20,100
-9,900
| -33% | -$53.3K | ﹤0.01% | 9534 |
|
|
2019
Q2 | $180K | Sell |
30,000
-97,700
| -77% | -$735K | ﹤0.01% | 9219 |
|
|
2019
Q1 | $1.15M | Buy |
127,700
+117,300
| +1,128% | +$997K | ﹤0.01% | 4763 |
|
|
2018
Q4 | $86K | Sell |
10,400
-14,800
| -59% | -$152K | ﹤0.01% | 8283 |
|
|
2018
Q3 | $348K | Buy |
+25,200
| New | +$204K | ﹤0.01% | 7182 |
|
Other funds holding ALDX
KCM
KCM
6CM
Jeff Yass's ALDX Position: Q2 2026 in Review
Jeff Yass reduced its Aldeyra Therapeutics (ALDX) stake by 79% in Q2 2026, selling an estimated $378K and leaving 58,398 shares worth $124K. The position accounts for ﹤0.01% of the portfolio, ranked #12337.
Jeff Yass first reported a position in ALDX in Q1 2018 and has held it in 33 quarters since. The position peaked at $10.9M in Q1 2023. 108 funds tracked by Wall St. Rank hold ALDX as of Q2 2026.
- Jeff Yass held 58,398 shares of Aldeyra Therapeutics worth $124K as of Q2 2026.
- Jeff Yass sold 220,044 Aldeyra Therapeutics shares in Q2 2026, an estimated $378K.
- Aldeyra Therapeutics made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #12337 holding.
- Jeff Yass first reported a position in Aldeyra Therapeutics in Q1 2018 and has held it in 33 quarters since.
- Jeff Yass's Aldeyra Therapeutics position peaked at $10.9M in Q1 2023.
- 108 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q2 2026.
Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.